Moteur de recherche d’entreprises européennes
Financement de l’UE (6 301 156 €) : La transplantation contrôlée d’organoïdes comme catalyseur de l’application de la médecine régénérative Hor27/11/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
La transplantation contrôlée d’organoïdes comme catalyseur de l’application de la médecine régénérative
End-stage liver failure is a major healthcare challenge. Liver diseases account for approximately 2 million deaths per year worldwide. Liver transplantation is the most effective way to re-establish a liver with normal functions for various diseases including acute liver failure or liver malignancies. Currently, less than 10% of global transplantation needs are met and the gap between patients on transplant waiting lists and available donor organs is steadily increasing. ORGANTRANS proposes a disruptive alternative to donor organs for patients with chronic or end-stage liver diseases who have still to isolate autologous liver stem cells. Driven by a need of leading European transplant centers, ORGANTRANS will tackle current obstacles for liver regenerative medicine by combining advanced know-how in cell biology, biomaterials, bioengineering, automation, standardization and clinical translation. ORGANTRANS will develop a liver tissue printing platform that will be shortly deployed under the “compassionate use exemption” by three leading European transplant centers belonging to the consortium or the External Advisory Board. ORGANTRANS will not only deliver an ATMP, but also platform technologies that can be scaled to other organ systems, as organoid technology is one of the largest parts of regenerative medicine. The project covers the entire value chain (from cell source, tissue engineering, bioprinting, post-processing to testing) allowing for early adoption of its results (product & process) in clinical practice. The platform will first be scaled to Europe and then to the rest of the world.
| Amires s.r.o. | 257 500 € |
| CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT | 1 172 441 € |
| DWI LEIBNIZ-INSTITUT FUR INTERAKTIVE MATERIALIEN e. V. | 538 975 € |
| King's College London | 257 500 € |
| KUGELMEIERS AG | 906 250 € |
| REGENHU SA | 1 162 718 € |
| UNIVERSITEIT UTRECHT | 1 419 898 € |
| VIB VZW | 585 875 € |
https://cordis.europa.eu/project/id/874586
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Amires s.r.o. - Financement de l’UE (6 301 156 €) : La transplantation contrôlée d’organoïdes comme catalyseur de l’application de la médecine régénérative"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
